Search
forLearn
5 / 801 resultslearn octapeptide-2
learn 18β-glycyrrhetinic acid
learn retinoic acid
learn copper tripeptide-1
Research
5 / 58 results
research 1345 A single-cell RNA map of perinatal developing mouse skin
The research mapped gene activity in developing mouse skin and found key markers for skin cell types and changes from fetal to early postnatal stages.
research Inhibition of Cholesterol Biosynthesis Modulates Epithelial-Mesenchymal Transition in Primary Cicatricial Alopecia Through TGFβ and Angiotensin Receptors
Blocking cholesterol production may help control hair loss in Primary Cicatricial Alopecia by affecting key regulators.
research Endogenous/exogenous stimuli‐responsive smart hydrogels for diabetic wound healing
Smart hydrogels can improve diabetic wound healing by adapting to wound conditions and providing controlled treatment.
research Efficient scarless skin regeneration enabled by loading micronized amnion in a bioinspired adhesive wound dressing
A new hydrogel with micronized amnion helps achieve better, scar-free skin healing.
research Harnessing mesenchymal aggregation for engineered organ‐level regeneration: Recent progress and perspective
Scientists are using clumps of special stem cells to improve organ repair.
Community Join
5 / 1000+ resultscommunity GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community AH-001 another topical AR degrader beside GT20029, completed Phase I
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
community Anagenic is trying to compound Gt20029
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
community CRISPR treatment for AGA on the horizon after approval for blood disorders
CRISPR treatments for blood disorders have been approved, leading to discussions about its potential for treating hair loss (AGA). A study showed that editing a gene related to DHT sensitivity could lead to hair regrowth, suggesting CRISPR may eventually be used for AGA, but it's expected to be expensive and not soon available.
community Protac degradation of the androgen receptor in mice shows good efficacy and no systemic drug could be found
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.